Drug Trial Radar · NCT03199885
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
190
Actual
Start
Apr 5, 2019
Primary completion
Apr 30, 2024
Study completion Apr 4, 2025
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells. \*NOTE: This study has a central confirmation step. The purpose of this step is to confirm by central testing that the patient's tumor has specific receptors. If the patient meets all the study requirements, the patient will join the study and begin therapy for breast cancer while the tumor is being tested.
Conditions
- Metastatic Breast Adenocarcinoma
- Metastatic HER2-Positive Breast Carcinoma
- Recurrent Breast Adenocarcinoma
- Recurrent HER2-Positive Breast Carcinoma
- Stage III Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Unresectable Breast Carcinoma
- Unresectable HER2-Positive Breast Carcinoma
Interventions
AtezolizumabDrug
Given IV
BiopsyProcedure
Undergo biopsy
Bone ScanProcedure
Undergo bone scan
Computed TomographyProcedure
Undergo CT scan
DocetaxelDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
PaclitaxelDrug
Given IV
PertuzumabBiological
Given IV
Placebo AdministrationOther
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
TrastuzumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: At the definitive analysis 2.5 years
Locations
673 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Katmai Oncology Group
Anchorage, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
CTCA at Western Regional Medical Center
Goodyear, Arizona
Banner-University Medical Center Phoenix
Phoenix, Arizona
Banner Boswell Medical Center
Sun City, Arizona
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
UC Irvine Health Cancer Center-Newport
Costa Mesa, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Dublin
Dublin, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Washington Hospital
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Kaiser Permanente - Harbor City
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
Loma Linda University Medical Center
Loma Linda, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Kaiser Permanente-Oakland
Oakland, California
Kaiser Permanente-Ontario
Ontario, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Desert Regional Medical Center
Palm Springs, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente - Panorama City
Panorama City, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Riverside
Riverside, California
Kaiser Permanente-Roseville
Roseville, California
Kaiser Permanente Downtown Commons
Sacramento, California
Showing 40 of 673 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.